Evidence map›Paper›PMID 20444892›Full record

ArticleJournal of virology2010

Murine gammaherpesvirus 68 LANA is essential for virus reactivation from splenocytes but not long-term carriage of viral genome.

Clinton R Paden, J Craig Forrest, Nathaniel J Moorman, Samuel H Speck

Abstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Deletion of Murine Gammaherpesvirus GeneJournal of virology · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Kaposi's Sarcoma Herpesvirus Genome Persistence.Frontiers in microbiology · 2016
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Clinton R PadenEmory Vaccine Center, Emory University School of Medicine, 1452 Clifton Road, Suite 429, Atlanta, GA 30322, USA.
J Craig Forrest
Nathaniel J Moorman
Samuel H Speck

Funding

Role of B Cells in Murine Gammaherpesvirus-68 LatencyR01CA095318 · NCI · EMORY UNIVERSITY · PI SCHARER, CHRISTOPHER D · 2003 to 2019
$4.9M
Function of the Gamma HV68 M2 AntigenR01AI058057 · NIAID · EMORY UNIVERSITY · PI SPECK, SAMUEL H · 2004 to 2016
$4.5M
Control of Gammaherpesvirus ReplicationR01CA052004 · NCI · WASHINGTON UNIVERSITY · PI SPECK, SAMUEL H · 1990 to 2013
$4.1M
CHARACTERIZATION OF THE GAMMA HV68 V CYCLINR01CA087650 · NCI · WASHINGTON UNIVERSITY · PI SPECK, SAMUEL H · 2000 to 2011
$3.2M
REGULATION OF EBV TRANSCRIPTION IN BURKITTS LYMPHOMAR01CA058524 · NCI · WASHINGTON UNIVERSITY · PI SPECK, SAMUEL H · 1995 to 2009
$2.4M
Role of gammaHV68 M1 antigen in Vbeta4+ T cell expansion and fibrosisR01AI073830 · NIAID · EMORY UNIVERSITY · PI SPECK, SAMUEL H · 2008 to 2012
$2.0M
NCI NIH HHS R01 CA052004NCI NIH HHS R01 CA058524NCI NIH HHS R01 CA087650NCI NIH HHS R01 CA095318NCI NIH HHS R01 CA52004NIAID NIH HHS R01 AI058057NIAID NIH HHS R01 AI073830NIAID NIH HHS R01 AI58057
6 · The paper itself

Abstract

ORF73, which encodes the latency-associated nuclear antigen (LANA), is a conserved gamma-2-herpesvirus gene. The murine gammaherpesvirus 68 (MHV68) LANA (mLANA) is critical for efficient virus replication and the establishment of latent infection following intranasal inoculation. To test whether the initial host immune response limits the capacity of mLANA-null virus to traffic to and establish latency in the spleen, we infected type I interferon receptor knockout (IFN-alpha/betaR(-/-)) mice via intranasal inoculation and observed the presence of viral genome-positive splenocytes at day 18 postinfection at approximately 10-fold-lower levels than in the genetically repaired marker rescue-infected mice. However, no mLANA-null virus reactivation from infected IFN-alpha/betaR(-/-) splenocytes was observed. To more thoroughly define a role of mLANA in MHV68 infection, we evaluated the capacity of an mLANA-null virus to establish and maintain infection apart from restriction in the lungs of immunocompetent mice. At day 18 following intraperitoneal infection of C57BL/6 mice, the mLANA-null virus was able to establish a chronic infection in the spleen albeit at a 5-fold-reduced level. However, as in IFN-alpha/betaR(-/-) mice, little or no virus reactivation could be detected from mLANA-null virus-infected splenocytes upon explant. An examination of peritoneal exudate cells (PECs) following intraperitoneal inoculation revealed nearly equivalent frequencies of PECs harboring the mLANA-null virus relative to the marker rescue virus. Furthermore, although significantly compromised, mLANA-null virus reactivation from PECs was detected upon explant. Notably, at later times postinfection, the frequency of mLANA-null genome-positive splenocytes was indistinguishable from that of marker rescue virus-infected animals. Analyses of viral genome-positive splenocytes revealed the absence of viral episomes in mLANA-null infected mice, suggesting that the viral genome is integrated or maintained in a linear state. Thus, these data provide the first evidence that a LANA homolog is directly involved in the formation and/or maintenance of an extrachromosomal viral episome in vivo, which is likely required for the reactivation of MHV68.

Indexed as

Genome, ViralVirus ActivationVirus LatencyAdministration, IntranasalAnimalsAntigens, ViralCells, CulturedGene Expression Regulation, ViralImmunity, InnateLungMiceMice, Inbred C57BLMice, KnockoutNuclear ProteinsPlasmidsReceptors, InterferonAntigens, Virallatency-associated nuclear antigenNuclear ProteinsReceptors, Interferon

Identifiers

PMID20444892
PMCPMC2898264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.